Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · IQVIA (IQV)

IQVIA appoints Nobel laureate William Kaelin Jr. to its board of directors

Neutral Impact 2 of 5 leadership Written later

IQVIA's board appointed Dr. William G. Kaelin Jr. as a director effective November 5, 2025, and the board determined he is independent under New York Stock Exchange rules. The filing discloses a board addition only and contains no financial results or guidance.

Key points

  • Dr. William G. Kaelin Jr. appointed to the board on November 5, 2025
  • Board determined Dr. Kaelin meets the NYSE definition of independent director
  • He will receive non-employee director compensation and sign the standard indemnification agreement
  • Dr. Kaelin shared the 2019 Nobel Prize in Physiology or Medicine and serves on the board of Eli Lilly and Company

The filing

CompanyIQVIA (IQV)
Form8-K, current report
Filed with the SECNov 5, 2025, 4:29 PM ET
Accession number0001193125-25-267053

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.